Skip to content
Parakho

Q1 FY27, unaudited

Revenue
₹376.66 Cr
Profit after tax
₹5.58 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations376.661,365.30
Other income9.5629.67
Total income386.221,394.97
Employee benefit expense59.67211.92
Finance costs21.7386.46
Depreciation & amortisation39.57119.80
Total expenses378.741,329.97
Profit before tax7.489.62
Tax expense1.90-4.96
Profit after tax5.5814.58
Total comprehensive income5.5814.66
Earnings per share
Earnings per share, basic₹0.37₹1.03
Earnings per share, diluted₹0.37₹1.02

Q1 FY27 unaudited, from the company’s filing with NSE. Source

FY26 from the company’s filing with NSE. Source

Why the dash

Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.

Earnings call

Q1 FY27

HCG reported Q1 FY27 revenue of INR6,951 million, up approximately 13% year-on-year, driven by an 11% increase in patient volumes and 2% ARPP growth. Adjusted EBITDA rose 20% year-on-year to INR1,339 million with margins improving to 19.4% from 18.2% in Q1 FY26. Management discussed the North Bangalore hospital ramp-up, bed capacity expansion plans, the completed Fertility business divestment, and use of rights issue proceeds for debt repayment and the Vizag stake increase.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 49 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 25 Aug 2026.